

UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DATE MAILED:

			1725 0	vvasningto	on, D.C. 20231	工の
·	APPLICATION NO.	FILING DATE	FIRST NAME	D INVENTOR		ATTORNEY DOCKET NO.
	08/981,087	05/27/98	ELMORE		М	1581.0200000
	- HM12/0227 NIXON & VANDERHYE P.C 1100 NORTH GLEBE ROAD, 8TH FL.			, 7		EXAMINER
					TURNE	R,S
					ART UNIT	PAPER NUMBER
	ARLINGTON V	/A 22201-471	4		1647	17

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

02/27/01



UNITED STES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

ART UNIT

PAPER NUMBER

08/981,08	87	STATES OF P	<u> </u>	
SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
				_,
				EXAMINER
		•		· .

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Turner whose telephone number is (703) 308-0056. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Gary Kunz whose telephone number is (703) 308-4623. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Sdurner a-az-o

CHRISTINE J. BAOUD
PRIMARY EXAMINER
Thustine D. Saoud

Application No.: ()8/98/, 087

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

		\cdot
Ø	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
		. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
Ø	7	Other: Claim 5, 6, 11, 28 and 30 refer to amino acid requences which are not referred to by seg ID NO as required.
Αp	p	licant Must Provide:
ΧÍ		An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
\square	i	An i nitial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entr nto the specification.
Ø	1	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	or	questions regarding compliance to these requirements, please contact:
Fo Fo	or or	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support Technical Assistance
		PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY